Literature DB >> 11086134

Identification of a K(d)-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84.

Rafaela Holtappels1, Doris Thomas1, Matthias J Reddehase1.   

Abstract

The two sister cytomegaloviruses (CMVs), human and murine CMV, have both evolved immune evasion functions that interfere with the major histocompatibility complex class I (MHC-I) pathway of antigen processing and presentation and are effectual in the early (E) phase of virus gene expression. However, studies on murine CMV have shown that E-phase immune evasion is leaky. An E-phase protein involved in immune evasion, namely m04-gp34, was found to simultaneously account for an antigenic peptide presented by the MHC-I molecule D(d). Recent work has demonstrated the induction of protective immunity specific for the E-phase protein M84-p65, one of two murine CMV homologues of the human CMV matrix protein UL83-pp65. In this study, the identification of the MHC-I K(d)-restricted M84 peptide (297)AYAGLFTPL(305) is documented. This peptide is the third antigenic peptide described for murine CMV and the second that escapes immunosubversive mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086134     DOI: 10.1099/0022-1317-81-12-3037

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

6.  Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.

Authors:  Marcus-Folker Pahl-Seibert; Markus Juelch; Jürgen Podlech; Doris Thomas; Petra Deegen; Matthias J Reddehase; Rafaela Holtappels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Authors:  Bala Vamsi K Karuturi; Shailendra B Tallapaka; Joy A Phillips; Sam D Sanderson; Joseph A Vetro
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

8.  Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions.

Authors:  Rafaela Holtappels; Natascha K A Grzimek; Christian O Simon; Doris Thomas; Doris Dreis; Matthias J Reddehase
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.

Authors:  Christopher S Morello; Ming Ye; Deborah H Spector
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

10.  Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.